drugset / Trial / NCT01328821

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

NCT01328821

Phase 1 Completed 38 enrolled Concert Pharmaceuticals
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CTP-499 following single dose administration.

Timeline

Start
2011-03
Primary completion
2011-04
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator CTP-499 Small molecule 400 mg
Comparator CTP-499 Small molecule 600 mg
Comparator CTP-499 Small molecule 1200 mg
Comparator CTP-499 Small molecule 1800 mg
Comparator CTP-499 Small molecule 2400 mg